Home › NCT07479173
Effects of P24 on Postprandial Aminoacidemia
Effects of an Acid-Active Protease (P24) on Postprandial Aminoacidemia Following a Standardized Mixed-Protein Burger Meal in Healthy Adults
Who can join
Ages 45 to 75 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Healthy adults aged 45-75 years * BMI 18.5-35 kg/m2 * Able to provide informed consent and comply with study procedure * Willing to consume the standardized mixed-protein test meal Exclusion Criteria: * BMI outside of 18.5-35 kg/m2 * Gastrointestinal disorders or malabsorption syndromes that could affect digestion/absorption (e.g., inflammatory bowel disease, celiac disease) * Diagnosed diabetes * Current use of medications or supplements that materially affect glucose metabolism or digestion (e.g., GLP-1 receptor agonists, chronic digestive enzyme supplementation) * Resting blood pressure ≥ 140/90 mmHg * Self-reported cancer within past 5 years * Known allergy or intolerance to meal components or capsule ingredients * Self-reported anemia or other conditions that increase risk from blood draws * Pregnancy or breastfeeding * Current smoking or nicotine use, heavy alcohol use (defined as \> 5 drinks/day or \> 15 drinks/week), or other factors that in the investigator's judgment make participation unsafe
About the study
The purpose of this study is to quantify the acute effects of an acid-active protease enzyme supplement (P24) on postprandial aminoacidemia following consumption of a standardized mixed-protein meal containing both plant- and animal-derived protein sources. Secondary objectives include evaluating the postprandial plasma peptidomic response, characterizing the postprandial hormonal responses (GLP-1, insulin, and GIP), and assessing the postprandial glucose response using standardized capillary blood glucose measurements. The study will also evaluate subjective responses including satiety and hunger and gastrointestinal symptoms.
What is being tested
- Protease enzyme supplement (dietary supplement)
- Placebo (other)
Sponsor: Amplifye · Participants: 30 · Started: Sep 5, 2026
Contact the study team
- Roberta Holt, PhD · Phone: 530-400-5952
Official record on ClinicalTrials.gov — NCT07479173
Locations in the U.S.
| California | Ragle Human Nutrition Center, Davis |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.